Table 1 Patients, tumor, and systemic therapy characteristics
| Â | IOERT boost arm | EBRT boost arm | p value |
|---|---|---|---|
Women in each arm | 125 (51%) | 110 (49%) | Â |
Median age (range) | 56.3 years (29–75) | 56.2 years (34–75) | 0.96** |
Menopausal status | 0.81* | ||
 Pre | 37 (30%) | 31 (28%) |  |
 Post | 88 (70%) | 79 (72%) |  |
Disease laterality | 0.73* | ||
 Right breast | 54 (43%) | 50 (45%) |  |
 Left breast | 71 (57%) | 60 (55%) |  |
Histology | 0.46* | ||
 IDC | 61 (49%) | 59 (54%) |  |
 ILC | 17 (14%) | 11 (10%) |  |
 DCIS | 3 (1.4%) | 3 (2.6%) |  |
 IDC+DCIS | 32 (26%) | 24 (22%) |  |
 Medullary | 6 (5%) | 4 (3.5%) |  |
 ILC+ILCS | 5 (4%) | 5 (4.4%) |  |
 Missing | 1 (0.6%) | 4 (3.5%) |  |
Pathologic T stage | 0.38* | ||
 pT1 | 96 (77%) | 79 (72%) |  |
 pT2 | 28 (22%) | 22 (20%) |  |
 pT3–pT4 | 1 (1%) | 1 (1%) |  |
 Missing | 0 | 8 (7%) |  |
Pathologic N stage | 0.55* | ||
 pN0 | 82 (65%) | 68 (62%) |  |
 pN1 | 38 (30%) | 32 (29%) |  |
 pN2 | 2 (2.1%) | 1 (1%) |  |
 pN3 | 1 (0.8%) | 1 (1%) |  |
 Missing | 2 (2.1%) | 8 (7%) |  |
Adjuvant chemotherapy | 0.61* | ||
 Yes | 37 (30%) | 36 (33%) |  |
 Not | 85 (68%) | 64 (58%) |  |
 Missing | 3 (2%) | 10 (9%) |  |
Hormone therapy | 0.66* | ||
 Yes | 105 (84%) | 90 (81%) |  |
 Not | 19 (15%) | 12 (11%) |  |
 Missing | 1 (1%) | 8 (8%) |  |